Trial Profile
Lamotrigine Extended-Release in Elderly Patients With Epilepsy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2023
Price :
$35
*
At a glance
- Drugs Lamotrigine (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 23 Jan 2018 Results assessing the effect of Age-Related Factors on the PK of Lamotrigine and Potential Implications for Dose Optimisation in patients data obtained from NCT00043875, NCT00144872, NCT00113165, NCT00104416, NCT00516139, NCT00264615 published in the Clinical Pharmacokinetics
- 11 Apr 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.